共 599 条
[81]
Edge S(2012)Reasons physicians do not recommend and patients refuse adjuvant chemotherapy for stage III colon cancer: a population based chart review BMC Res Notes 109 2410-4894
[82]
Blayney DW(2007)The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer Cancer 52 482-1259
[83]
Wilson J(2014)Prostate cancer treatment and survival: evidence for men with prevalent comorbid conditions Med Care 24 4888-1211
[84]
Hudis C(2006)Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer J Clin Oncol 330 1253-2317
[85]
Ottesen R(2014)Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer J Clin Oncol 90 1205-444
[86]
Hughes ME(1994)Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma N Engl J Med 32 2311-468
[87]
Carroll JP(1998)Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer J Natl Cancer Inst 379 432-933
[88]
Protani MM(2014)Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (alliance) J Clin Oncol 23 455-1792
[89]
Nguyen L(2012)Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100000 women in 123 randomised trials Lancet 65 924-1020
[90]
Cheng ME(1970)The pre-therapeutic classification of co-morbidity in chronic disease J Chron Dis 353 1784-1468